To include your compound in the COVID-19 Resource Center, submit it here.

Aptinyx starts Phase II trial of NYX-2925 to treat neuropathic pain

Aptinyx Inc. (Evanston, Ill.) began a Phase II trial of NYX-2925 to treat neuropathic pain associated

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE